Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
for Pancreatic Adenocarcinoma
1 location in Dallas
Sponsor: Baylor Research Institute
Sex: All·Age: 18+
Code: NCT04926467·Phase 2·Recruiting·Listed Jun 2021
Oncology Clinical Trials in Dallas, TX
As of July 2026, 304 paid clinical trials are recruiting for Oncology in Dallas, Texas. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
310 clinical trials for Oncology
·Clear filters·↓ Download CSVNeratinib in Combination With Ruxolitinib in Patients With mTNBC
for Metastatic Triple-Negative Breast Carcinoma
Drug: Ruxolitinib
1 location in Dallas
Sponsor: Baylor Research Institute
Sex: Female·Age: 18+
Code: NCT06008275·EARLY_Phase 1·Recruiting·Listed Aug 2023
Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
for Bladder Cancer
1 location in Dallas
Sponsor: University of Texas Southwestern Medical Center
Sex: All·Age: 18+
Code: NCT06394570·Phase 1, Phase 2·Recruiting·Listed May 2024
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
for Hematologic Malignancy
29 locations incl. Los Angeles
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
Sex: All·Age: 1 - 21
Code: NCT05476770·Phase 1·Recruiting·Listed Jul 2022
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
for Esophagus Adenocarcinoma
1 location in Dallas
Sponsor: Dallas VA Medical Center
Sex: All·Age: 18+
Code: NCT04018872·Phase 2·Recruiting·Listed Jul 2019
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
for Gastric Cancer
Drug: Sonesitatug vedotin
83 locations incl. Mobile
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT07431281·Phase 3·Recruiting·Listed Feb 2026
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
for Urothelial Cancer
38 locations incl. Los Angeles
Sponsor: Daiichi Sankyo
Sex: All·Age: 18+
Code: NCT07129993·Phase 2, Phase 3·Recruiting·Listed Aug 2025
DESTINY-PANTUMOUR04
for Adenocarcinoma (NOS)
17 locations incl. Birmingham
Sponsor: AstraZeneca
Sex: All·Age: 18 - 130
Code: NCT07124000·Recruiting·Listed Aug 2025
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
for Lymphoma, Non-Hodgkin
23 locations incl. Duarte
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07101328·Phase 1·Recruiting·Listed Aug 2025
Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus
for Barrett Esophagus
6 locations incl. Kansas City
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06732388·Phase 2·Recruiting·Listed Dec 2024
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
for Cancer
7 locations incl. Coon Rapids
Sponsor: Helio Genomics
Sex: All·Age: 18+
Code: NCT05181826·Recruiting·Listed Jan 2022
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
for Biliary Tract Cancer
Drug: Rilvegostomig
48 locations incl. Scottsdale
Sponsor: AstraZeneca
Sex: All·Age: 18 - 99
Code: NCT06467357·Phase 3·Recruiting·Listed Jun 2024
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
for Non-small Cell Lung Cancer
18 locations incl. Duarte
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06218914·Phase 1·Recruiting·Listed Jan 2024
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
for Solid Tumors
18 locations incl. Birmingham
Sponsor: GlaxoSmithKline
Sex: All·Age: 18+
Code: NCT06431594·Phase 1·Recruiting·Listed May 2024
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
for Breast Cancer
Drug: Durvalumab
64 locations incl. Daphne
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06103864·Phase 3·Recruiting·Listed Oct 2023
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
for Renal Cell Carcinoma (RCC)
46 locations incl. Phoenix
Sponsor: Exelixis
Sex: All·Age: 18+
Code: NCT05176483·Phase 1·Recruiting·Listed Jan 2022
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
for HER2-positive Gastric Cancer
Drug: Rilvegostomig
55 locations incl. Anchorage
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06764875·Phase 3·Recruiting·Listed Jan 2025
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
for Neoplasms
15 locations incl. Stanford
Sponsor: GlaxoSmithKline
Sex: All·Age: 18+
Code: NCT06551142·Phase 1·Recruiting·Listed Aug 2024
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
for HNSCC
9 locations incl. Denver
Sponsor: Normunity AccelCo, Inc.
Sex: All·Age: 18+
Code: NCT07182149·Phase 1·Recruiting·Listed Sep 2025
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
for Solid Tumor
17 locations incl. Duarte
Sponsor: Biohaven Therapeutics Ltd.
Sex: All·Age: 18+
Code: NCT06384807·Phase 1, Phase 2·Recruiting·Listed Apr 2024
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
for Melanoma (Skin)
5 locations incl. La Jolla
Sponsor: Hummingbird Bioscience
Sex: All·Age: 18+
Code: NCT06956690·Phase 1, Phase 2·Recruiting·Listed May 2025
Study of AZD0754 in Participants With Metastatic Prostate Cancer
for Metastatic Prostate Cancer
13 locations incl. Duarte
Sponsor: AstraZeneca
Sex: Male·Age: 18 - 130
Code: NCT06267729·Phase 1, Phase 2·Recruiting·Listed Feb 2024
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
for Triple Negative Breast Cancer
10 locations incl. Denver
Sponsor: Dren Bio
Sex: All·Age: 18+
Code: NCT06999187·Phase 1·Recruiting·Listed May 2025
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
for Hepatocellular Carcinoma
1 location in Dallas
Sponsor: Can-Fite BioPharma
Sex: All·Age: 18+
Code: NCT05201404·Phase 3·Recruiting·Listed Jan 2022
Conditions in Oncology (Dallas, TX)
Solid tumor· 63Non-small cell lung cancer (NSCLC)· 44Breast cancer· 41Cancer (any)· 24Prostate cancer· 23Colorectal cancer· 22Pancreatic cancer· 20Gastric cancer· 18Bladder cancer· 18Endometrial cancer· 17Ovarian cancer· 15Acute myeloid leukemia (AML)· 15Kidney cancer· 14Hematologic malignancy· 13Esophageal cancer· 12Non-Hodgkin lymphoma· 12Metastatic breast cancer· 11Head and neck cancer· 11Multiple myeloma· 10Neuroblastoma· 10Triple-negative breast cancer· 8Liver cancer· 8Biliary tract cancer· 7Cervical cancer· 7Melanoma· 7Lung cancer· 6Gastroesophageal junction cancer· 6Chronic lymphocytic leukemia (CLL)· 6Leukemia (other)· 6Myelodysplastic syndromes (MDS)· 6Small cell lung cancer· 5Fallopian tube cancer· 5Diffuse large B-cell lymphoma (DLBCL)· 5HER2-negative breast cancer· 4Metastatic prostate cancer· 4Follicular lymphoma· 4Skin cancer· 4Osteosarcoma· 4HER2-positive breast cancer· 3Glioblastoma· 3Glioma· 3Ewing sarcoma· 3Mesothelioma· 3Neuroendocrine tumors· 3Metastatic colorectal cancer· 2Chronic myelomonocytic leukemia· 2Myelofibrosis· 2Myeloproliferative neoplasm· 2Hodgkin lymphoma· 2Mantle cell lymphoma· 2Small lymphocytic lymphoma· 2Sarcoma· 2Rhabdomyosarcoma· 2Rectal cancer· 1Uterine cancer· 1Brain cancer· 1Brain metastases· 1Acute lymphoblastic leukemia· 1Marginal zone lymphoma· 1Burkitt lymphoma· 1Thyroid cancer· 1